Barclays Merchant Bank Singapore sold 4,93,893 shares in Shilpa Medicare (representing 0.6 percent of the total paid-up equity) at Rs 560.21 per share on the NSE.
Nippon India Mutual Fund was the buyer for some of those shares sold by existing investors
The drug is used to treat patients suffering from Advanced Renal Cell Carcinoma (RCC).
In addition, Shilpa Medicare said it decided to acquire FTF Pharma for Rs 75 crore. It will also acquire Auxilla Pharmaceuticals and Research LLP through its subsidiary Shilpa Corporate Holdings, it added.
According to ICICI Securities, Buy Shilpa Medicare in the range of Rs 440.00–458.00 for target price of Rs 535.00 with a stop loss of Rs 405.00. Time Frame: Six months.
IBRUSHIL (Ibrutinib 140 mg) capsules is being manufactured in the state-of-the-art US-FDA approved manufacturing facility.
The products are being manufactured and supplied from the state-of-the-art US-FDA approved manufacturing facility.
According to the company, the drug is expected to be available in the UK in the second quarter of 2020.
The drug is expected to be available in the UK in the second quarter of 2020.
The company is preparing responses to the observations, which will be submitted to the Agency within 15 business days.
The sale of biological unit is subject to the approval of shareholders and is expected to be completed on or before March 31.
The company has received USFDA tentative approval for its ANDA Pirfenidone tablets.
An EIR is given to a unit on successful closure of an inspection conducted by the United States Food and Drug Administration (USFDA).
Erlotinib is a generic equivalent of reference listed drug (RLD) Tarceva.
The stock witnessed spurt in volume by more than 1.17 times. It was trading with volumes of 3,249 shares, compared to its five-day average of 1,886 shares, an increase of 72.27 percent.
The US market for Gemcitabine is approximately $ 11.7 million.
The company has received US Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA), Gemcitabine for injection USP in the strengths of 200 mg/vial and 1 g/vial, Shilpa Medicare said in a BSE filing.
Motilal Oswal is bullish on Shilpa Medicare has recommended buy rating on the stock with a target price of Rs 620 in its research report dated January 19, 2019.